+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

CSF GABA levels in Parkinson's disease



CSF GABA levels in Parkinson's disease



Advances in Neurology 40: 427-430



CSF levels of GABA were investigated in a group of Parkinson patients without drug treatment and a group of Parkinson patients under treatment with L-DOPA or anticholinergics. Probenecid results in an elevation of CSF GABA levels in healthy persons. The results indicate a significant decrease of GABA levels in CSF in untreated Parkinson patients. Parkinson patients treated with L-DOPA or anticholinergics show nearly normal CSF GABA levels. This may suggest that the altered GABA function in Parkinson's disease is secondary to changes in the dopamine system.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 042429225

Download citation: RISBibTeXText

PMID: 6695622


Related references

CSF and plasma GABA levels in Parkinson's disease. Journal of Neurology Neurosurgery and Psychiatry 45(3): 253-256, 1982

Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 tesla proton MRS. Plos one 7(1): E30918, 2012

Parkinson's disease severity levels and MDS-Unified Parkinson's Disease Rating Scale. Parkinsonism and Related Disorders 21(1): 50-54, 2015

GABA signalling: therapeutic targets for epilepsy, Parkinson's disease and Huntington's disease. Expert Opinion on Therapeutic Targets 5(2): 219-239, 2001

Neurosteroid and GABA-A receptor alterations in Alzheimer's disease, Parkinson's disease and multiple sclerosis. Neuroscience 191: 6, 2011

An in vivo ultrahigh field 14.1 T (1) H-MRS study on 6-OHDA and α-synuclein-based rat models of Parkinson's disease: GABA as an early disease marker. Nmr in Biomedicine 26(1): 43-50, 2013

GABA-B receptor: possible target for Parkinson's disease therapy. Experimental Neurology 233(1): 121-122, 2012

Parkinson's Disease and Neurodegeneration: GABA-Collapse Hypothesis. Frontiers in Neuroscience 10: 269, 2016

GABA-dopamine relationship in Parkinson's disease striatum. Advances in Neurology 45: 75-77, 1987

GABA: Inhibition brings new excitement in Parkinson's disease. Movement Disorders 31(3): 297, 2016

Flumazenil, a GABA antagonist, may improve features of Parkinson's disease. Movement Disorders 18(6): 683-685, 2003

GABA receptors and levodopa-induced motor complications in Parkinson disease. Society for Neuroscience Abstracts 27(2): 2571, 2001

Injection of GABA-agonist into globus pallidus in patient with Parkinson's disease. Lancet 351(9099): 340-341, 1998

Possible role of GABA-B receptor modulation in MPTP induced Parkinson's disease in rats. Experimental and Toxicologic Pathology 67(2): 211-217, 2015

Gamma vinyl GABA in the treatment of levodopa-induced dyskinesias in Parkinson's disease. Journal of Neurology Neurosurgery and Psychiatry 55(5): 413, 1992